FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3001639096> ?p ?o ?g. }

• W3001639096 endingPage "154984" @default.
• W3001639096 startingPage "154984" @default.
• W3001639096 abstract "Interleukin-2 (IL-2) was the cornerstone treatment for metastatic renal cell carcinoma (RCC) until the advent of tyrosine kinase inhibitors, but it still has therapeutic value. As a single bolus of IL-2 causes toxicity, there is interest in administration regimens with better tolerability and efficacy. Chronotherapy is the administration of therapy according to the circadian rhythm’s influence on the immune and hormonal systems. This phase I-II trial evaluated the safety of IL-2 chronotherapy in metastatic RCC patients and determined the maximum tolerated dose. The secondary objective was to identify prognostic factors for survival. Three chronomodulation schedules (5:00–13:00, 13:00–21:00, and 21:00–5:00) were tested. Each schedule was an 8-h IL-2 infusion, with a Gaussian distribution of drug concentration peaking at 4 h. To identify the maximum tolerated dose, the dose for different patients was escalated from 2 MIU/m2 (level I) to 18.6 MIU/m2 (level VI). Thirty patients were enrolled and completed treatment. Two patients were treated at 5:00–13:00, 15 at 13:00–21:00, and 13 at 21:00–5:00. Nine cases of grade 3 toxicity occurred in 7 patients at the highest dose (18.6 MIU/m2); no grade 4 toxicity occurred. The maximum tolerated dose was 14.0 MUI/m2. Patients were followed for a median of 16 months (range, 2–107). One patient was lost to follow-up, 3 patients were alive at last contact, and 26 patients died. Six patients achieved long-term survival (≥48 months). There was one complete response, four partial responses, 11 cases of stable disease and 14 of progressive disease. The response rate was 16% (5/30) and disease-control rate was 53% (16/30). Median progression-free survival was 4.5 months, and median overall survival was 14.5 months. Kaplan-Meier analyses revealed significant associations between overall survival and ECOG performance score (0 vs. 1–2), MSKCC score (0–2 vs. ≥ 3), IMDC risk score (0–2 vs. ≥ 3), IL-2 dose level (IV-VI vs. I-III), and prolactin (increase vs. no increase), and but not for chronotherapy schedule. IL-2 chronotherapy appears to be safe, moderately toxic and active in metastatic RCC. It may represent a new modality of IL-2 administration for these patients." @default.
• W3001639096 created "2020-01-30" @default.
• W3001639096 creator A5002711617 @default.
• W3001639096 creator A5010733466 @default.
• W3001639096 creator A5025051235 @default.
• W3001639096 creator A5029808551 @default.
• W3001639096 creator A5042033558 @default.
• W3001639096 creator A5073892178 @default.
• W3001639096 creator A5075416139 @default.
• W3001639096 creator A5078960065 @default.
• W3001639096 creator A5082512614 @default.
• W3001639096 creator A5086777398 @default.
• W3001639096 creator A5090395553 @default.
• W3001639096 date "2020-04-01" @default.
• W3001639096 modified "2023-09-27" @default.
• W3001639096 title "Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study" @default.
• W3001639096 cites W1592968073 @default.
• W3001639096 cites W1953744580 @default.
• W3001639096 cites W1986634084 @default.
• W3001639096 cites W1989561452 @default.
• W3001639096 cites W1992350807 @default.
• W3001639096 cites W2016336310 @default.
• W3001639096 cites W2028606939 @default.
• W3001639096 cites W2089628522 @default.
• W3001639096 cites W2098064548 @default.
• W3001639096 cites W2098136315 @default.
• W3001639096 cites W2099088585 @default.
• W3001639096 cites W2099752220 @default.
• W3001639096 cites W2106453307 @default.
• W3001639096 cites W2114124506 @default.
• W3001639096 cites W2116949558 @default.
• W3001639096 cites W2123784879 @default.
• W3001639096 cites W2128643078 @default.
• W3001639096 cites W2135139265 @default.
• W3001639096 cites W2148741545 @default.
• W3001639096 cites W2162104455 @default.
• W3001639096 cites W2165195703 @default.
• W3001639096 cites W2171469612 @default.
• W3001639096 cites W2222086386 @default.
• W3001639096 cites W2268972797 @default.
• W3001639096 cites W2505217913 @default.
• W3001639096 cites W2530419161 @default.
• W3001639096 cites W2792937256 @default.
• W3001639096 cites W2889646458 @default.
• W3001639096 cites W2918019324 @default.
• W3001639096 cites W2929554293 @default.
• W3001639096 cites W4211057115 @default.
• W3001639096 doi "https://doi.org/10.1016/j.cyto.2019.154984" @default.
• W3001639096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31972343" @default.
• W3001639096 hasPublicationYear "2020" @default.
• W3001639096 type Work @default.
• W3001639096 sameAs 3001639096 @default.
• W3001639096 citedByCount "14" @default.
• W3001639096 countsByYear W30016390962020 @default.
• W3001639096 countsByYear W30016390962021 @default.
• W3001639096 countsByYear W30016390962022 @default.
• W3001639096 countsByYear W30016390962023 @default.
• W3001639096 crossrefType "journal-article" @default.
• W3001639096 hasAuthorship W3001639096A5002711617 @default.
• W3001639096 hasAuthorship W3001639096A5010733466 @default.
• W3001639096 hasAuthorship W3001639096A5025051235 @default.
• W3001639096 hasAuthorship W3001639096A5029808551 @default.
• W3001639096 hasAuthorship W3001639096A5042033558 @default.
• W3001639096 hasAuthorship W3001639096A5073892178 @default.
• W3001639096 hasAuthorship W3001639096A5075416139 @default.
• W3001639096 hasAuthorship W3001639096A5078960065 @default.
• W3001639096 hasAuthorship W3001639096A5082512614 @default.
• W3001639096 hasAuthorship W3001639096A5086777398 @default.
• W3001639096 hasAuthorship W3001639096A5090395553 @default.
• W3001639096 hasConcept C121446783 @default.
• W3001639096 hasConcept C126322002 @default.
• W3001639096 hasConcept C126894567 @default.
• W3001639096 hasConcept C197934379 @default.
• W3001639096 hasConcept C2777472916 @default.
• W3001639096 hasConcept C2778375690 @default.
• W3001639096 hasConcept C2779490328 @default.
• W3001639096 hasConcept C2779910239 @default.
• W3001639096 hasConcept C29730261 @default.
• W3001639096 hasConcept C43376680 @default.
• W3001639096 hasConcept C71924100 @default.
• W3001639096 hasConcept C90924648 @default.
• W3001639096 hasConceptScore W3001639096C121446783 @default.
• W3001639096 hasConceptScore W3001639096C126322002 @default.
• W3001639096 hasConceptScore W3001639096C126894567 @default.
• W3001639096 hasConceptScore W3001639096C197934379 @default.
• W3001639096 hasConceptScore W3001639096C2777472916 @default.
• W3001639096 hasConceptScore W3001639096C2778375690 @default.
• W3001639096 hasConceptScore W3001639096C2779490328 @default.
• W3001639096 hasConceptScore W3001639096C2779910239 @default.
• W3001639096 hasConceptScore W3001639096C29730261 @default.
• W3001639096 hasConceptScore W3001639096C43376680 @default.
• W3001639096 hasConceptScore W3001639096C71924100 @default.
• W3001639096 hasConceptScore W3001639096C90924648 @default.
• W3001639096 hasLocation W30016390961 @default.
• W3001639096 hasOpenAccess W3001639096 @default.
• W3001639096 hasPrimaryLocation W30016390961 @default.
• W3001639096 hasRelatedWork W1992943540 @default.
• W3001639096 hasRelatedWork W1998081924 @default.

• next